2nd Quarter - Amendment

HELIX, INC. for HELIX, INC.

Firm
Client
Income
—
Expenses
$130,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 5, 2023 $40,000 Replaced
2nd Quarter - Amendment (this page) Jul 26, 2023 $130,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases, opportunities to use genetic testing to justify insurance coverage for specific treatments

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC)

Budget/Appropriations BUD

HR 812 Inflation Reduction Act, including Defense Health, Viral Surveillance funding, COVID Supplemental allocations And funding needs, reauthorization for the ability for certain agencies to pull appropriations and enter into contracts in relation to the Pandemic & All Hazards Preparedness Act Discussion Drafts, including wastewater surveillance, viral surveillance and sequencing, data modernization, Center for Forecasting and Analytics, ASPR

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Disease Control & Prevention (CDC)

Bills named: H.R. 812 (118th)

Science/Technology SCI

Pharmacogenomic testing, insurance coverage opportunities for whole exome sequencing and specific testing for genetic diseases. And the regulation of lab developed tests. US H 1526 Medicare Hereditary Cancer USH2369 In Vitro Tests US S 765 Hereditary Cancer Genetic Testing

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Defense DEF

Coordination with public health and other entities around biosecurity efforts in viral surveillance and sequencing for known and unknown pathogens, including Disease X, data needed to develop medical countermeasures, and Defense Health funding inclusive of genetic testing.

LobbyistCovered position, as disclosed
KELLI ARTHUR HYKES —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.